• Neurocrine Biosciences today launched a Phase 2 trial of NBI-'567 as an add-on treatment for cognitive impairment in mild to moderate Alzheimer's disease.
• The study will enroll approximately 135 adults ages 50 to 85 receiving stable acetylcholinesterase inhibitor treatment.
• Participants will receive a high or low once-daily oral dose, or placebo, over 12 weeks.
• The trial will assess whether NBI-'567 improves cognitive performance, while evaluating safety and tolerability.
• No results have been presented; the study is newly initiated.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neurocrine Biosciences Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202610200830PR_NEWS_USPR_____LA76018) on October 20, 2026, and is solely responsible for the information contained therein.